3649 results for «684»
3649 results
M-TEER for primary mitral regurgitation
08 Feb 2025 – From PCR Tokyo Valves 2025
In this PCR Tokyo Valves 2025 session on M-TEER for primary mitral regurgitation, gain valuable insights starting with an overview of current TEER devices. Benefit from four case studies that highlight the features of these devices, explore strategies to prevent mitral regurgitation recurrence post-TEER, and delve...
M-TEER around the world
08 Feb 2025 – From PCR Tokyo Valves 2025
Explore the latest insights and advancements in the field of Mitral Transcatheter Edge-to-Edge Repair (M-TEER) from around the world. Discover a new anatomical risk score for predicting procedural outcomes, two-year outcomes from the MiCLASP study, the impact of regurgitant volume to left atrial volume ratio on...
M-TEER difficult situation: small mitral valves, P2 prolapse & leaflet degeneration
08 Feb 2025 – From PCR Tokyo Valves 2025
Explore a series of challenging cases in Mitral Transcatheter Edge-to-Edge Repair (M-TEER), highlighting the versatility and adaptability of this technique. Discover how M-TEER can be successfully applied in patients with extremely small mitral valves, P2 prolapse supported by chordae from the posterior papillary muscle, wide prolapse...
TAVI complications: hemolytic anemia, prosthetic valve endocarditis & stroke
08 Feb 2025 – From PCR Tokyo Valves 2025
Gain valuable insights into the management of complications associated with Transcatheter Aortic Valve Implantation (TAVI). Discover the latest evidence on hemolytic anemia, the predictive value of the hemoglobin to creatinine ratio, outcomes of transcarotid TAVI, a case study on prosthetic valve endocarditis, the role of diastolic...
Management of mitral regurgitation patients undergoing TMVI screening
13 Jan 2022
This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.
PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial
18 May 2021
Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)
01 Apr 2025
Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.
Author
30 years of primary PCI – a tale of perseverance
16 May 2023
Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.
Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial
05 Mar 2023
Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.
Author
